AliveCor touts KardiaBand studies
AliveCor touted data today from two new studies showing that its portable electrocardiogram tech can accurately detect atrial fibrillation and hyperkalemia.
Researchers at the Cleveland Clinic studied the company’s KardiaBand for Apple Watch and reported that the system detected AFib and normal sinus rhythm at a rate comparable to doctors interpreting the same ECGs.
The Kardia algorithm distinguished between AFib and normal sinus rhythm with 93% sensitivity and 84% specificity, according to AliveCor. Doctors achieved 99% sensitivity.
AliveCor’s KardiaBand is the only FDA-approved medical device accessory available in the U.S. for the Apple Watch.
Additional research showed that KardiaBand combined with new artificial intelligence could non-invasively detect high potassium levels in blood – or hyperkalemia.
The study used two million ECGs linked with 4 million serum potassium values aggregated between 1994 and 2017, as well as data from an AliveCor smartphone ECG system, to design an AI algorithm that could detect hyperkalemia.
AliveCor touted that the system could detect hyperkalemia with 90-94% sensitivity.
“As our team continues to push the bounds on innovation in digital health, we are on a path to changing the way AFib and hyperkalemia can be detected, and to defining the ways in which products like Apple Watch can play a role in the future of health care,” CEO Vic Gundotra said in prepared remarks.
NEXT: J&J’s Janssen, iRhythm report data from ECG patch study